INTERVIEW: OncoMed CEO Hastings on milestones ahead
This article was originally published in Scrip
OncoMed Pharmaceuticals has no imminent plans to finance its soon-to-be seven-asset clinical pipeline by selling stock, because the cancer therapy developer's partnerships are structured in a way that "keeps us from having to raise money, which is a corporate goal for the company," chairman and CEO Paul Hastings told Scrip.
You may also be interested in...
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.